ClinicalTrials.gg
CompletedNCT03310580Updated Dec 23, 2019Results posted

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

A Phase 2 interventional study of AR-13324 Ophthalmic Solution 0.02% and AR-13324 Ophthalmic Solution 0.04% in Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by Aerie Pharmaceuticals. Completed at 40 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-23.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
12th of 17
42 · median 85
Started
2017
with 1 other
Phase 2
6 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 12th largest by enrollment, is one of 2 that started in 2017, is one of 6 in phase 2, and was the 8th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To test the safety and effectiveness of AR-13324 0.02% and 0.04% ophthalmic solution relative to placebo in Japanese/Japanese-American subjects with open-angle glaucoma or ocular hypertension in US.

03

Conditions studied

  • Primary Open Angle Glaucoma or Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be 18 years or older
  2. Be of Japanese ethnicity within the 2nd generation defined as (a) 1st generation born in Japan, immigrated to US and (b) 2nd generation - parents are 1st generation and patient was born in US as an American citizen
  3. Diagnosis of open-angle glaucoma or ocular hypertension in both eyes
  4. Medicated intraocular pressure >/= 15 mmHg and \< 30 mmHg in both eyes at screening
  5. OAG eyes - unmedicated IOP >/= 15 mmHg and \< 35 mmHg at 2 qualification visits at 08:00, 10:00 and 16:00
  6. OHT eyes - unmedicated IOP >/= 22 mmHg and \< 35mmHg at 08:00, 10:00 and 16:00
  7. Best corrected visual acuity + 1.0 logMAR or better by ETDRS in each eye
  8. Able to give signed and follow instructions

Exclusion criteria

Exclusion Criteria:

  1. ocular disease
  2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma or narrow angles
  3. Intraocular pressure >/=35 mmHg in either eye
  4. Ocular hyperemia score of moderate (+2) at qualification visit #2
  5. Previous glaucoma intraocular surgery
  6. Refractive surgery in either eye
  7. Ocular injury within 6 months prior to screening or ocular surgery or non-refractive laser treatment within 3 months prior to screening
  8. Recent or current ocular infection or inflammation in either eye
  9. Use of ocular medication in either eye of any kind within 30 days of screening and throughout the study
  10. Mean central corneal thickness > 620 µm in either eye
  11. Any abnormality preventing reliable applanation tonometry of either eye
  12. Known to benzalkonium chloride or of netarsudil ophthalmic solution
  13. Clinically significant abnormalities in screening lab tests
  14. Clinically significant systemic disease that might interfere with the study
  15. Participated in any study within 30 days prior to screening
  16. Systemic medication that could have a substantial effect on IOP within 30 days prior to screening or anticipated during the study
  17. Women of who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    AR-13324 Ophthalmic Solution 0.02%

    Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days

    Drug: AR-13324 Ophthalmic Solution 0.02%

  • Experimental
    AR-13324 Ophthalmic Solution 0.04%

    Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days

    Drug: AR-13324 Ophthalmic Solution 0.04%

  • Placebo comparator
    Placebo Comparator

    Topical sterile ophthalmic solution; 1 drop daily to each eye for 28 days

    Drug: AR-13324 Ophthalmic Solution Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Diurnal IOP (Intraocular Pressure) (mmHg)

    Mean diurnal intraocular pressure (IOP) at week 4, measured by Goldman Applanation Tonometry (GAT).

    Time frame: 28 Days

Secondary outcomes

  1. Extent of Exposure

    Exposure to study medication in days for all treatment groups

    Time frame: 28 Days

07

Results

Posted Nov 15, 2019

Participant flow

Participant flow — Overall Study
MilestoneAR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo Comparator
Started151512
Completed151412
Not completed010
Withdrew: Adverse event010

Outcome measures

PrimaryMean Diurnal IOP (Intraocular Pressure) (mmHg)

Mean diurnal intraocular pressure (IOP) at week 4, measured by Goldman Applanation Tonometry (GAT).

Time frame:
28 Days
Reported as:
Mean · mmHg
Mean Diurnal IOP (Intraocular Pressure) (mmHg)
mmHgAR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo Comparator
Mean Diurnal IOP (Intraocular Pressure) (mmHg)14.35 ± 0.54914.33 ± 0.56717.32 ± 0.576
SecondaryExtent of Exposure

Exposure to study medication in days for all treatment groups

Time frame:
28 Days
Reported as:
Mean · Days
Extent of Exposure
DaysAR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo Comparator
Extent of Exposure27.9 ± 1.9126.8 ± 7.5627.4 ± 2.23

Adverse events

Collected over Adverse Event data was collected during the course of the study of 28 days and after 30 days safety follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AR-13324 Ophthalmic Solution 0.02%0/15 (0%)0/15 (0%)10/15 (66.7%)
AR-13324 Ophthalmic Solution 0.04%0/14 (0%)0/14 (0%)11/14 (78.6%)
Placebo Comparator0/12 (0%)0/12 (0%)3/12 (25%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventAR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo Comparator
Conjunctival hyperaemiaEye disorders10/1510/140/12
Eye PruritusEye disorders0/152/141/12
Conjunctival hemorrhageEye disorders0/152/140/12
vision blurredEye disorders2/150/140/12
Dry eyeEye disorders0/151/141/12
Viral Upper Respiratory Tract InfectionInfections and infestations0/150/141/12
Pain in ExtremityMusculoskeletal and connective tissue disorders0/150/141/12
Eyelid margin crustingEye disorders0/151/140/12
Eyelids pruritusEye disorders0/151/140/12
Instillation site painGeneral disorders0/151/140/12

Baseline characteristics

Intent to Treat Population (ITT)

Age, Categorical
Age, Categorical(Participants)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
<=18 years0000
Between 18 and 65 years88622
>=65 years66618
Age, Continuous
Age, Continuous(years)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
Mean61.1 ± 20.3260.9 ± 12.1265.6 ± 14.9862.4 ± 15.95
Sex: Female, Male
Sex: Female, Male(Participants)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
Female1011829
Male43411
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
Hispanic or Latino0000
Not Hispanic or Latino14141240
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
Japanese 1st Generation1112629
Japanese 2nd Generation32611
Region of Enrollment
Region of Enrollment(participants)AR-13324 Ophthalmic Solution 0.02%AR-13324 Ophthalmic Solution 0.04%Placebo ComparatorTotal
United States14141240
08

Study locations

40 sites
  • Arizona Eye Center
    Chandler, Arizona 85224, United States
  • Arizona Glaucoma Specialists
    Phoenix, Arizona 85050, United States
  • Milton M. Hom, OD FAAO FACAAISc
    Azusa, California 91702, United States
  • Havana Research Institute
    Burbank, California 91506, United States
  • Global Research Management
    Glendale, California 91204, United States
  • Southern California Eye Physicians & Surgeons
    Los Alamitos, California 90270, United States
  • East West Eye Institute
    Los Angeles, California 90013, United States
  • USC Roski Eye Institute University of Souther California
    Los Angeles, California 90033, United States
  • Global Research Foundation
    Los Angeles, California 90041, United States
  • The Eye Research Foundation
    Newport Beach, California 92663, United States
  • Southern California Eye Physicians Surgeons
    Pasadena, California 91105, United States
  • North Bay Eye Associates Inc.
    Petaluma, California 94954, United States
  • Martel Eye
    Rancho Cordova, California 95670, United States
  • University of California
    San Diego, California 92093, United States
  • AdvanceMed Clinical Research
    San Diego, California 92122, United States
  • Glaucoma Center of San Francisco
    San Francisco, California 94105, United States
  • Samsum Clinic
    Santa Barbara, California 93110, United States
  • MCB Clinical Research Centers LLC
    Colorado Springs, Colorado 80910, United States
  • Clayton Eye Clinical Research, LLC
    Morrow, Georgia 30260, United States
  • Jenkins Eye Care
    Honolulu, Hawaii 96814, United States
  • Winward Eye Physicians and Eye Surgeons
    Kailua, Hawaii 96704, United States
  • Island Eye Care, Inc.
    Kailua, Hawaii 96740, United States
  • They Eye Care Institute
    Louisville, Kentucky 40206, United States
  • University of Michigan
    Ann Arbor, Michigan 48105, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Emil A. Stein MD Ltd
    Las Vegas, Nevada 89119, United States
  • AdvanceMed Clinical Research
    Las Vegas, Nevada 89123, United States
  • New York Eye Infirmary of Mount Sinai
    New York, New York 10003, United States
  • The Shimmyo Group
    New York, New York 10016, United States
  • Manhattan Eye Ear and Throat Hospital
    New York, New York 10065, United States
  • Optimed Research
    Marysville, Ohio 43040, United States
  • Glaucoma Consultants and Center for Eye Research, PA
    Mount Pleasant, South Carolina 29464, United States
  • University Eye Specialists
    Maryville, Tennessee 37803, United States
  • VRF Eye Speciality Group
    Memphis, Tennessee 38120, United States
  • Lake Travis Eye and Laser Center
    Lakeway, Texas 78734, United States
  • DCT - Shah Research LLC dba Discovery Clinical Trials
    Mission, Texas 78572, United States
  • Round Rock Eye Consultants
    Round Rock, Texas 78681, United States
  • San Antonio Eye Center
    San Antonio, Texas 78215, United States
  • R and R Eye Research LLC
    San Antonio, Texas 78229, United States
  • Emerson Clinical Research Institute
    Falls Church, Virginia 22046, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Oct 2018, 11 months.

Results were first posted in Nov 2019, 1 year after primary completion.

Of 38 industry-sponsored phase 2 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 11 months is close to that.

Counting every sponsor, half of 41 studies reached it within 11 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Oct 16, 2017
StartActual
Nov 15, 2017
Primary completionActual
Oct 25, 2018
CompletionActual
Oct 25, 2018
Results first posted
Nov 15, 2019
Last update
Dec 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03310580
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Nov 15, 2017
Primary completion
Oct 25, 2018
Completion
Oct 25, 2018
Results posted
Nov 15, 2019
Last update
Dec 23, 2019

Study contacts

Nancy Ramirez-Davis
study director · Aerie Pharmaceuticals

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion